Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 745 across all filing types
Latest filing 2010-06-29 Capital/Financing Update
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB SCIENCE - AB Science and its partners receive €10m from OSEO
Capital/Financing Update Classification · 95% confidence The document is a press release dated June 29, 2010, announcing that AB Science and its partners received €10 million from OSEO for the APAS-IPK project related to developing anti-cancer drugs. This announcement details funding, project objectives, and the roles of the participating companies (AB Science, Bull, Genomic Vision, Skuld-Tech). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement concerning financing and strategic development activities, specifically receiving grant funding/advances for R&D. This fits best under 'Capital/Financing Update' (CAP) as it details a significant capital injection/grant for development, or potentially 'Regulatory Filings' (RNS) if it were a general announcement, but CAP is more specific to the content of receiving funds for development. Given the focus on receiving €10m in advances and subsidies for a strategic project, CAP is the most appropriate classification.
2010-06-29 English
AB SCIENCE - Contrat de liquidité
Capital/Financing Update Classification · 95% confidence The document announces the establishment of a liquidity contract ('contrat de liquidité') with Société Générale Securities, effective June 23, 2010. This action involves managing the company's stock liquidity, which is a specific type of financing or capital market activity. It is not an Annual Report (10-K), Earnings Release (ER), or a standard dividend notice (DIV). The closest fit among the provided definitions is 'Capital/Financing Update' (CAP), as liquidity contracts are mechanisms related to capital structure management and market support. It is a direct announcement of a financial arrangement, not a general regulatory filing (RNS) or a report publication announcement (RPA).
2010-06-24 French
AB SCIENCE - Liquidity contract
Capital/Financing Update Classification · 95% confidence The document announces that AB Science has concluded a liquidity contract with Société Générale Securities, effective from June 23, 2010, until December 31, 2010. This action relates to market stimulation of its shares, which is a form of capital management or financing activity, specifically related to share liquidity/market making. This fits best under 'Capital/Financing Update' (CAP), as it involves a formal agreement impacting the trading and structure around the company's shares, although it is not a direct issuance or repurchase. It is not an earnings release, management change, or standard regulatory filing like a 10-K or IR. Given the context of market support agreements, CAP is the most appropriate classification among the provided options.
2010-06-24 English
AB SCIENCE - EXERCICE DE LA CLAUSE DE SURALLOCATION
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated May 4, 2010, announcing the finalization of an Initial Public Offering (IPO) for AB Science. Specifically, it states that the overall size of the IPO has been increased to 31.6 million euros following the full exercise of the over-allotment option ('option de sur allocation'). This relates directly to fundraising, financing activities, and capital structure changes associated with going public. This content aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), but rather the substantive announcement of the financing outcome.
2010-05-04 French
AB SCIENCE - EXERCISE OF THE OVER-ALLOTMENT OPTION
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 04, 2010, announcing the finalization of an Initial Public Offering (IPO) for AB Science. Specifically, it details the full exercise of the over-allotment option, resulting in an increased total IPO size of €31.6 million. This announcement concerns fundraising, capital structure changes related to the offering, and the associated legal/prospectus information. This clearly falls under the definition of 'Capital/Financing Update' (CAP), as it is a direct report on the outcome of a financing activity (the IPO). It is not a full 10-K, an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital raising.
2010-05-04 English
Succès de l’introduction en bourse d’AB Science sur le Compartiment B de NYSE Euronext
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the definitive terms and successful completion of AB Science's Initial Public Offering (IPO) on Euronext Paris. It details the offer price (€12.65), the total amount raised (€16.5M for the company, €27.5M gross proceeds), the breakdown between new and existing shares, the allocation between the Global Placement and the Public Offer (OPO), and the listing schedule. This content directly relates to fundraising, capital structure changes, and the issuance of new shares to the public market. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the core details of the financing event itself.
2010-04-23 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.